Tags

Type your tag names separated by a space and hit enter

Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
Cytometry B Clin Cytom. 2007 Sep; 72(5):363-70.CB

Abstract

BACKGROUND

The success of treatment using monoclonal antibodies in oncology is influenced by, among other factors, the level of target antigen expression on tumor cells. The authors analyzed the intensity of the CD52 antigen expression in patients with chronic lymphoproliferative diseases and compared them with B-lymphocytes of a healthy population and CD34(+) cells in peripheral blood stem cells (PBSC) grafts.

METHODS

Recently diagnosed and previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL), mantle-cell lymphoma (MCL), or small lymphocytic lymphoma (SLL) were evaluated and compared with control group and CD34(+) cells. The intensity of CD52 was expressed in molecules of equivalent soluble fluorochrome units (MESF) and antibody-binding capacity (ABC).

RESULTS

In the group of patients with B-CLL, the CD52 level on tumor cells (245 x 10(3) MESF; 107 x 10(3) ABC) was significantly lower than on B-lymphocytes of the control group (446 x 10(3) MESF; 194 x 10(3) ABC; P < 0.001) and SLL tumor cells (526 x 10(3) MESF; 229 x 10(3) ABC; P < 0.001). The CD52 antigen was expressed on a majority of CD34(+) cells, but its expression intensity was low (101 x 10(3) MESF; 44 x 10(3) ABC).

CONCLUSIONS

Our data demonstrate differences in the intensity of the CD52 antigen expression between B-lymphocytes and tumor lymphocytes of B-CLL patients, and between B-CLL and SLL tumor cells. CD52 antigen is expressed at low level on CD34(+) cells.

Authors+Show Affiliations

Laboratory of Flow Cytometry and Cellular Therapy, Faculty of Medicine, Masaryk University, Komenskeho nam. 2, 662 43 Brno, Czech Republic. mklabus@fnbrno.czNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17428002

Citation

Klabusay, Martin, et al. "Different Levels of CD52 Antigen Expression Evaluated By Quantitative Fluorescence Cytometry Are Detected On B-lymphocytes, CD 34+ Cells and Tumor Cells of Patients With Chronic B-cell Lymphoproliferative Diseases." Cytometry. Part B, Clinical Cytometry, vol. 72, no. 5, 2007, pp. 363-70.
Klabusay M, Sukova V, Coupek P, et al. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. Cytometry B Clin Cytom. 2007;72(5):363-70.
Klabusay, M., Sukova, V., Coupek, P., Brychtova, Y., & Mayer, J. (2007). Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. Cytometry. Part B, Clinical Cytometry, 72(5), 363-70.
Klabusay M, et al. Different Levels of CD52 Antigen Expression Evaluated By Quantitative Fluorescence Cytometry Are Detected On B-lymphocytes, CD 34+ Cells and Tumor Cells of Patients With Chronic B-cell Lymphoproliferative Diseases. Cytometry B Clin Cytom. 2007;72(5):363-70. PubMed PMID: 17428002.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. AU - Klabusay,Martin, AU - Sukova,Vera, AU - Coupek,Petr, AU - Brychtova,Yvona, AU - Mayer,Jiri, PY - 2007/4/13/pubmed PY - 2007/11/2/medline PY - 2007/4/13/entrez SP - 363 EP - 70 JF - Cytometry. Part B, Clinical cytometry JO - Cytometry B Clin Cytom VL - 72 IS - 5 N2 - BACKGROUND: The success of treatment using monoclonal antibodies in oncology is influenced by, among other factors, the level of target antigen expression on tumor cells. The authors analyzed the intensity of the CD52 antigen expression in patients with chronic lymphoproliferative diseases and compared them with B-lymphocytes of a healthy population and CD34(+) cells in peripheral blood stem cells (PBSC) grafts. METHODS: Recently diagnosed and previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL), mantle-cell lymphoma (MCL), or small lymphocytic lymphoma (SLL) were evaluated and compared with control group and CD34(+) cells. The intensity of CD52 was expressed in molecules of equivalent soluble fluorochrome units (MESF) and antibody-binding capacity (ABC). RESULTS: In the group of patients with B-CLL, the CD52 level on tumor cells (245 x 10(3) MESF; 107 x 10(3) ABC) was significantly lower than on B-lymphocytes of the control group (446 x 10(3) MESF; 194 x 10(3) ABC; P < 0.001) and SLL tumor cells (526 x 10(3) MESF; 229 x 10(3) ABC; P < 0.001). The CD52 antigen was expressed on a majority of CD34(+) cells, but its expression intensity was low (101 x 10(3) MESF; 44 x 10(3) ABC). CONCLUSIONS: Our data demonstrate differences in the intensity of the CD52 antigen expression between B-lymphocytes and tumor lymphocytes of B-CLL patients, and between B-CLL and SLL tumor cells. CD52 antigen is expressed at low level on CD34(+) cells. SN - 1552-4949 UR - https://www.unboundmedicine.com/medline/citation/17428002/Different_levels_of_CD52_antigen_expression_evaluated_by_quantitative_fluorescence_cytometry_are_detected_on_B_lymphocytes_CD_34+_cells_and_tumor_cells_of_patients_with_chronic_B_cell_lymphoproliferative_diseases_ L2 - https://doi.org/10.1002/cyto.b.20181 DB - PRIME DP - Unbound Medicine ER -